<h3>關鍵見解</h3>
<ul>
<li>Inhibikase Therapeutics 的重要個人投資者持股表明，關鍵決策受到更大公眾股東的影響</li>
<li>51% 的股份由前 11 大股東持有</li>
<li>Inhibikase Therapeutics 的機構持股比例為 30%</li>
</ul>
<p>特朗普承諾要 &#34;釋放&#34; 美國的石油和天然氣，這 15 只美國股票的發展有望受益。</p>
<p>每位 Inhibikase Therapeutics, Inc. (NASDAQ:IKT) 的投資者都應該瞭解最強大的股東羣體。個人投資者持有 39% 的股份，是公司最大股東。換句話説，該羣體在投資公司時將獲得最多（或失去最多）的收益。</p>
<p>雖然個人投資者是上週 11% 價格上漲後獲得最大收益的羣體，但機構也獲得了 30% 的收益。</p>
<p>在下面的圖表中，我們聚焦於 Inhibikase Therapeutics 的不同持股羣體。</p>
<p>查看我們對 Inhibikase Therapeutics 的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/113910012-ownership-breakdown-1-dark-2/1765881740832?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1642" height="732" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/113910012-ownership-breakdown-1-dark-2/1765881740832"/></p>
<p>NasdaqCM:IKT 持股分佈 2025 年 12 月 16 日</p>
<h2>機構持股對 Inhibikase Therapeutics 的啓示是什麼？</h2>
<p>許多機構將其業績與接近當地市場的指數進行比較。因此，他們通常更關注納入主要指數的公司。</p>
<p>我們可以看到 Inhibikase Therapeutics 確實有機構投資者，他們持有公司相當一部分的股票。這表明在專業投資者中有一定的可信度。但我們不能僅僅依賴這一事實，因為機構有時也會做出糟糕的投資，就像其他人一樣。當多個機構持有一隻股票時，總是存在他們處於 “擁擠交易” 的風險。當這種交易出現問題時，多個參與方可能會爭相快速出售股票。在沒有增長曆史的公司中，這種風險更高。您可以在下面看到 Inhibikase Therapeutics 的歷史收益和收入，但請記住，事情總是有更多的背景。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/113910012-earnings-and-revenue-growth-1-dark-2/1765881742801?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1642" height="1048" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/113910012-earnings-and-revenue-growth-1-dark-2/1765881742801"/></p>
<p>NasdaqCM:IKT 收益和收入增長 2025 年 12 月 16 日</p>
<p>看起來對沖基金持有 Inhibikase Therapeutics 11% 的股份。這很有趣，因為對沖基金可能非常活躍並且具有激進性。許多基金尋找中期催化劑，以推動股價上漲。Sands Capital Ventures, LLC 目前是最大股東，持有 11% 的流通股。相比之下，第二和第三大股東分別持有約 5.4% 和 5.2% 的股份。</p>
<p>查看股東登記，我們可以看到前 11 大股東控制了 51% 的股份，這意味着沒有單一股東擁有多數股權。</p>
<p>研究機構持股是評估和篩選股票預期表現的好方法。通過研究分析師的情緒也可以實現同樣的目的。覆蓋該股票的分析師很多，因此查看他們的預測也許值得。</p>
<h2>Inhibikase Therapeutics 的內部持股</h2>
<p>內部人的定義在不同國家之間可能略有不同，但董事會成員始終算在內。管理層最終對董事會負責。然而，管理者作為執行董事會成員並不罕見，特別是如果他們是創始人或首席執行官。</p>
<p>內部持股是積極的，當它表明領導層像公司的真正所有者一樣思考時。然而，高內部持股也可能賦予公司內部小團體巨大的權力。在某些情況下，這可能是負面的。</p>
<p>我們最新的數據表明，內部人持有一些 Inhibikase Therapeutics, Inc. 的股份。作為個人，內部人共同持有價值 790 萬美元的公司股份，公司的市值為 1.9 億美元。看到內部人有一些投資是好的，但我們通常希望看到更高的內部持股。檢查這些內部人是否在增持可能值得關注。</p>
<h2>公眾持股</h2>
<p>公眾——包括散户投資者——持有公司 39% 的股份，因此不能輕易被忽視。儘管這一持股規模相當可觀，但如果決策與其他大股東不同，可能不足以改變公司政策。</p>
<h2>私募股權持股</h2>
<p>私募股權公司持有 11% 的股份，能夠在以價值創造為重點的公司戰略中發揮作用。有時我們看到私募股權公司長期持有，但一般來説，他們的投資週期較短，並且——顧名思義——不太會投資於上市公司。經過一段時間，他們可能會考慮出售並將資本重新部署到其他地方。</p>
<h2>私人公司持股</h2>
<p>我們的數據表明，私人公司持有公司 5.0% 的股份。深入研究這一點可能值得。如果相關方，例如內部人，對這些私人公司之一有興趣，則應在年度報告中披露。私人公司也可能對公司有戰略利益。</p>
<h2>下一步：</h2>
<p>考慮擁有公司股份的不同羣體總是值得的。但要更好地理解 Inhibikase Therapeutics，我們需要考慮許多其他因素。例如，我們已經確定了 <strong>Inhibikase Therapeutics 的 4 個警示信號</strong>（其中 3 個可能是嚴重的），您應該注意。</p>
<p>但最終 <strong>未來</strong> 而不是過去，將決定這家公司的所有者將如何表現。因此，我們認為查看這份免費的報告，瞭解分析師是否預測更光明的未來是明智的。</p>
<p>注意：本文中的數據是使用過去十二個月的數據計算的，指的是財務報表日期所在月份的最後一天結束的 12 個月期間。這可能與全年年度報告數據不一致。</p>
<p>國防和災難的移動基礎設施</p>
<p>下一波機器人技術不是人形機器人，而是能夠在 30 分鐘內在任何地方提供 5G、ISR 和雷達的完全自主塔。</p>
<p>在下一輪合同之前獲取投資者簡報</p>
<p>代表 CiTech 贊助</p>

<p>Inhibikase Therapeutics（納斯達克代碼：IKT）上週股價上漲了 11%，最受益的是持有 39% 股份的散户投資者。機構持有 30% 的股份，而對沖基金和私募股權公司各持有 11%。前 11 大股東控制着公司 51% 的股份。內部持股價值為 790 萬美元。公眾的持股比例雖然可觀，但單獨不足以影響公司的政策</p>

<h3>Key Insights</h3>
<div class="lb-trans"><h3>關鍵見解</h3>
</div><ul>
<li>Inhibikase Therapeutics' significant individual investors ownership suggests that the key decisions are influenced by shareholders from the larger public</li>
<li>51% of the business is held by the top 11 shareholders</li>
<li>Institutional ownership in Inhibikase Therapeutics is 30%</li>
</ul>
<div class="lb-trans"><ul>
<li>Inhibikase Therapeutics 的重要個人投資者持股表明，關鍵決策受到更大公眾股東的影響</li>
<li>51% 的股份由前 11 大股東持有</li>
<li>Inhibikase Therapeutics 的機構持股比例為 30%</li>
</ul>
</div><p>Trump has pledged to &#34;unleash&#34; American oil and gas and these 15 US stocks have developments that are poised to benefit.</p>
<div class="lb-trans"><p>特朗普承諾要 &#34;釋放&#34; 美國的石油和天然氣，這 15 只美國股票的發展有望受益。</p>
</div><p>Every investor in Inhibikase Therapeutics, Inc. (NASDAQ:IKT) should be aware of the most powerful shareholder groups. With 39% stake, individual investors possess the maximum shares in the company. In other words, the group stands to gain the most (or lose the most) from their investment into the company.</p>
<div class="lb-trans"><p>每位 Inhibikase Therapeutics, Inc. (NASDAQ:IKT) 的投資者都應該瞭解最強大的股東羣體。個人投資者持有 39% 的股份，是公司最大股東。換句話説，該羣體在投資公司時將獲得最多（或失去最多）的收益。</p>
</div><p>While individual investors were the group that reaped the most benefits after last week’s 11% price gain, institutions also received a 30% cut.</p>
<div class="lb-trans"><p>雖然個人投資者是上週 11% 價格上漲後獲得最大收益的羣體，但機構也獲得了 30% 的收益。</p>
</div><p>In the chart below, we zoom in on the different ownership groups of Inhibikase Therapeutics.</p>
<div class="lb-trans"><p>在下面的圖表中，我們聚焦於 Inhibikase Therapeutics 的不同持股羣體。</p>
</div><p>Check out our latest analysis for Inhibikase Therapeutics</p>
<div class="lb-trans"><p>查看我們對 Inhibikase Therapeutics 的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/113910012-ownership-breakdown-1-dark-2/1765881740832" alt="" original-src="https://images.simplywall.st/asset/chart/113910012-ownership-breakdown-1-dark-2/1765881740832"/></p>
<p>NasdaqCM:IKT Ownership Breakdown December 16th 2025</p>
<div class="lb-trans"><p>NasdaqCM:IKT 持股分佈 2025 年 12 月 16 日</p>
</div><h2>What Does The Institutional Ownership Tell Us About Inhibikase Therapeutics?</h2>
<div class="lb-trans"><h2>機構持股對 Inhibikase Therapeutics 的啓示是什麼？</h2>
</div><p>Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.</p>
<div class="lb-trans"><p>許多機構將其業績與接近當地市場的指數進行比較。因此，他們通常更關注納入主要指數的公司。</p>
</div><p>We can see that Inhibikase Therapeutics does have institutional investors; and they hold a good portion of the company's stock. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Inhibikase Therapeutics' historic earnings and revenue below, but keep in mind there's always more to the story.</p>
<div class="lb-trans"><p>我們可以看到 Inhibikase Therapeutics 確實有機構投資者，他們持有公司相當一部分的股票。這表明在專業投資者中有一定的可信度。但我們不能僅僅依賴這一事實，因為機構有時也會做出糟糕的投資，就像其他人一樣。當多個機構持有一隻股票時，總是存在他們處於 “擁擠交易” 的風險。當這種交易出現問題時，多個參與方可能會爭相快速出售股票。在沒有增長曆史的公司中，這種風險更高。您可以在下面看到 Inhibikase Therapeutics 的歷史收益和收入，但請記住，事情總是有更多的背景。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/113910012-earnings-and-revenue-growth-1-dark-2/1765881742801" alt="" original-src="https://images.simplywall.st/asset/chart/113910012-earnings-and-revenue-growth-1-dark-2/1765881742801"/></p>
<p>NasdaqCM:IKT Earnings and Revenue Growth December 16th 2025</p>
<div class="lb-trans"><p>NasdaqCM:IKT 收益和收入增長 2025 年 12 月 16 日</p>
</div><p>It looks like hedge funds own 11% of Inhibikase Therapeutics shares. That's interesting, because hedge funds can be quite active and activist. Many look for medium term catalysts that will drive the share price higher. Sands Capital Ventures, LLC is currently the largest shareholder, with 11% of shares outstanding. In comparison, the second and third largest shareholders hold about 5.4% and 5.2% of the stock.</p>
<div class="lb-trans"><p>看起來對沖基金持有 Inhibikase Therapeutics 11% 的股份。這很有趣，因為對沖基金可能非常活躍並且具有激進性。許多基金尋找中期催化劑，以推動股價上漲。Sands Capital Ventures, LLC 目前是最大股東，持有 11% 的流通股。相比之下，第二和第三大股東分別持有約 5.4% 和 5.2% 的股份。</p>
</div><p>Looking at the shareholder registry, we can see that 51% of the ownership is controlled by the top 11 shareholders, meaning that no single shareholder has a majority interest in the ownership.</p>
<div class="lb-trans"><p>查看股東登記，我們可以看到前 11 大股東控制了 51% 的股份，這意味着沒有單一股東擁有多數股權。</p>
</div><p>Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.</p>
<div class="lb-trans"><p>研究機構持股是評估和篩選股票預期表現的好方法。通過研究分析師的情緒也可以實現同樣的目的。覆蓋該股票的分析師很多，因此查看他們的預測也許值得。</p>
</div><h2>Insider Ownership Of Inhibikase Therapeutics</h2>
<div class="lb-trans"><h2>Inhibikase Therapeutics 的內部持股</h2>
</div><p>The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.</p>
<div class="lb-trans"><p>內部人的定義在不同國家之間可能略有不同，但董事會成員始終算在內。管理層最終對董事會負責。然而，管理者作為執行董事會成員並不罕見，特別是如果他們是創始人或首席執行官。</p>
</div><p>Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.</p>
<div class="lb-trans"><p>內部持股是積極的，當它表明領導層像公司的真正所有者一樣思考時。然而，高內部持股也可能賦予公司內部小團體巨大的權力。在某些情況下，這可能是負面的。</p>
</div><p>Our most recent data indicates that insiders own some shares in Inhibikase Therapeutics, Inc.. As individuals, the insiders collectively own US$7.9m worth of the US$190m company. It is good to see some investment by insiders, but we usually like to see higher insider holdings. It might be worth checking if those insiders have been buying.</p>
<div class="lb-trans"><p>我們最新的數據表明，內部人持有一些 Inhibikase Therapeutics, Inc. 的股份。作為個人，內部人共同持有價值 790 萬美元的公司股份，公司的市值為 1.9 億美元。看到內部人有一些投資是好的，但我們通常希望看到更高的內部持股。檢查這些內部人是否在增持可能值得關注。</p>
</div><h2>General Public Ownership</h2>
<div class="lb-trans"><h2>公眾持股</h2>
</div><p>The general public-- including retail investors -- own 39% stake in the company, and hence can't easily be ignored. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.</p>
<div class="lb-trans"><p>公眾——包括散户投資者——持有公司 39% 的股份，因此不能輕易被忽視。儘管這一持股規模相當可觀，但如果決策與其他大股東不同，可能不足以改變公司政策。</p>
</div><h2>Private Equity Ownership</h2>
<div class="lb-trans"><h2>私募股權持股</h2>
</div><p>With an ownership of 11%, private equity firms are in a position to play a role in shaping corporate strategy with a focus on value creation. Sometimes we see private equity stick around for the long term, but generally speaking they have a shorter investment horizon and -- as the name suggests -- don't invest in public companies much. After some time they may look to sell and redeploy capital elsewhere.</p>
<div class="lb-trans"><p>私募股權公司持有 11% 的股份，能夠在以價值創造為重點的公司戰略中發揮作用。有時我們看到私募股權公司長期持有，但一般來説，他們的投資週期較短，並且——顧名思義——不太會投資於上市公司。經過一段時間，他們可能會考慮出售並將資本重新部署到其他地方。</p>
</div><h2>Private Company Ownership</h2>
<div class="lb-trans"><h2>私人公司持股</h2>
</div><p>Our data indicates that Private Companies hold 5.0%, of the company's shares. It might be worth looking deeper into this. If related parties, such as insiders, have an interest in one of these private companies, that should be disclosed in the annual report. Private companies may also have a strategic interest in the company.</p>
<div class="lb-trans"><p>我們的數據表明，私人公司持有公司 5.0% 的股份。深入研究這一點可能值得。如果相關方，例如內部人，對這些私人公司之一有興趣，則應在年度報告中披露。私人公司也可能對公司有戰略利益。</p>
</div><h2>Next Steps:</h2>
<div class="lb-trans"><h2>下一步：</h2>
</div><p>It's always worth thinking about the different groups who own shares in a company. But to understand Inhibikase Therapeutics better, we need to consider many other factors. For instance, we've identified <strong>4 warning signs for Inhibikase Therapeutics</strong> (3 are potentially serious) that you should be aware of.</p>
<div class="lb-trans"><p>考慮擁有公司股份的不同羣體總是值得的。但要更好地理解 Inhibikase Therapeutics，我們需要考慮許多其他因素。例如，我們已經確定了 <strong>Inhibikase Therapeutics 的 4 個警示信號</strong>（其中 3 個可能是嚴重的），您應該注意。</p>
</div><p>But ultimately <strong>it is the future</strong>, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.</p>
<div class="lb-trans"><p>但最終 <strong>未來</strong> 而不是過去，將決定這家公司的所有者將如何表現。因此，我們認為查看這份免費的報告，瞭解分析師是否預測更光明的未來是明智的。</p>
</div><p>NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.</p>
<div class="lb-trans"><p>注意：本文中的數據是使用過去十二個月的數據計算的，指的是財務報表日期所在月份的最後一天結束的 12 個月期間。這可能與全年年度報告數據不一致。</p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>國防和災難的移動基礎設施</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波機器人技術不是人形機器人，而是能夠在 30 分鐘內在任何地方提供 5G、ISR 和雷達的完全自主塔。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一輪合同之前獲取投資者簡報</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>代表 CiTech 贊助</p>
</div>

While institutions invested in Inhibikase Therapeutics, Inc. (NASDAQ:IKT) benefited from last week's 11% gain, individual investors stood to gain the most

儘管機構投資者在 Inhibikase Therapeutics, Inc.（NASDAQ:IKT）中投資並從上週 11% 的漲幅中獲益，但個人投資者才是最大的受益者